The Department of Veterans Affairs strongly supports research to advance the health care of Veterans. As a VA-affiliated nonprofit organization, NFFRE enables VA research to be funded by non-VA sources such as the National Institutes of Health, industry sponsors, other non-profit organizations, and donations to NFFRE. With this non-VA funding, NFFRE provides a research platform that expands the research program of the VA Office of Research and Development and also works closely with the Research Service of the North Florida/South Georgia Veterans Health System (NF/SG VHS).
NFFRE provides VA researchers with assistance on all aspects of research, including pre-study development, regulatory requirements, and study management. Research projects conducted through NFFRE span all fields of medicine, other fields of health care such as physical therapy, and related biomedical fields such as engineering, where research focuses on areas such as imaging and prosthetics.
How to Volunteer and Participate in VA Research
Stories about current VA research: Research Currents
Active Study Spotlight
WARRIOR (Women’s Ischemia Trial to Reduce Events in Non-Obstructive CAD)
Principal Investigator: Carsten Schmalfuss, MD
The Ischemia-IMT (Ischemia-Intensive Medical Treatment Reduces Events in Women with Non-Obstructive CAD), subtitle: Women's Ischemia Trial to Reduce Events in Non-Obstructive CAD (WARRIOR) trial is a multicenter, prospective, randomized, blinded outcome evaluation (PROBE design) evaluating intensive statin/ACE-I (or ARB)/aspirin treatment (IMT) vs. usual care (UC) in 4,422 symptomatic women patients with symptoms and/or signs of ischemia but no obstructive CAD. This study is being conducted to determine whether intensive medical treatment to modify risk factors and vascular function in women patients with coronary arteries showing no flow limit obstruction but with cardiac symptoms (i.e., chest pain, shortness of breath) will reduce the patient's likelihood of dying, having a heart attack, stroke/TIA or being hospitalized for cardiac reasons. The results will provide evidence data necessary to inform future guidelines regarding how best to treat this growing population of patients, and ultimately improve the patient's cardiac health and quality of life and reduce health-care costs.
CHRONICLE (A Longitudinal Prospective Observational Study of the Characteristics, Treatment Patterns and Health Outcomes of Individuals with Severe Asthma in the United States)
Principal Investigator: Peruvemba S. Sriram, MD
The CHRONICLE Study will provide a contemporary description of the epidemiology and medical management of US adults with severe asthma who have not achieved control with high-dose ICS therapy and additional controllers. Additionally, the study will describe the use of and outcomes associated with recently approved monoclonal antibody therapies for severe asthma. The primary objective of the CHRONICLE Study is to describe patient characteristics, treatment patterns, and health outcomes among a large, geographically diverse cohort of US adults with severe asthma who are not controlled on high-dose ICS with additional controllers and/or require chronic systemic corticosteroid or monoclonal antibody therapy.
ASLeap (A Randomized, Double-blind, Parallel-group, Multicenter Study of Secukinumab to Compare 300 mg and 150 mg at Week 52 in Patients With Ankylosing Spondylitis Who Are Randomized to Dose Escalation After Not Achieving Inactive Disease During an Initial 16 Weeks of Open-label Treatment With Secukinumab 150 mg)
Principal Investigator: Michael Bubb, MD
This randomized, double-blind, parallel-group, multicenter study of secukinumab is designed to estimate the difference in clinical response between 300 mg and 150 mg of secukinumab at Week 52, which follows randomization to dose escalation at Week 16 for patients with Ankylosing Spondylitis who inadequately respond to open-label secukinumab 150 mg. This study will also investigate the association between treatment andsleep disturbances, as well as daytime activity patterns.